Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)

@article{Agarwal2020ConvalescentPI,
  title={Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)},
  author={Anup Agarwal and Aparna Mukherjee and Gunjan Kumar and Pranab Chatterjee and Tarun Bhatnagar and Pankaj Malhotra},
  journal={The BMJ},
  year={2020},
  volume={371}
}
Abstract Objective To investigate the effectiveness of using convalescent plasma to treat moderate coronavirus disease 2019 (covid-19) in adults in India. Design Open label, parallel arm, phase II, multicentre, randomised controlled trial. Setting 39 public and private hospitals across India. Participants 464 adults (≥18 years) admitted to hospital (screened 22 April to 14 July 2020) with confirmed moderate covid-19 (partial pressure of oxygen in arterial blood/fraction of inspired oxygen (PaO2… Expand
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
TLDR
Among patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes. Expand
A randomized, double-blind, controlled trial of convalescent plasma in adults with severe COVID-19
TLDR
In adults hospitalized with severe COVID-19, use of convalescent plasma was not associated with significant improvement in 28 days clinical status, however, asignificant improvement in mortality was observed, which warrants further evaluation. Expand
Safety and Efficacy of Convalescent Plasma for Severe COVID-19: Interim Report of a Multicenter Phase II Study from Saudi Arabia
TLDR
CP containing detectable antibodies is a safe strategy and may result in a decrease in mortality in patients with severe COVID-19, and the results of a larger study sample would provide more clarity if this difference in mortality is significant. Expand
Convalescent plasma for hospitalized patients with COVID-19 and the effect of plasma antibodies: a randomized controlled, open-label trial
TLDR
Convalescent plasma did not reduce the risk of intubation or death at 30 days among hospitalized patients with COVID-19 and transfusion of convalescence plasma with unfavourable antibody profiles may be associated with worse clinical outcomes compared to standard care. Expand
Adjunctive treatment with high-titre convalescent plasma in severely and critically ill COVID-19 patients – a safe but futile intervention. A comparative cohort study
TLDR
Convalescent plasma containing antibodies derived from coronavirus disease 2019 survivors has been proposed as a promising therapeutic option for severe COVID-19 and was a very safe intervention, with no effect on mortality. Expand
Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease
TLDR
The study did show that CP therapy appears to be safe in hospitalized COVID-19 patients with hypoxia, although a larger definitive study is needed for confirmation. Expand
A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia.
TLDR
CP showed a significant benefit in preventing progression to non-invasive ventilation or high-flow oxygen, invasive mechanical ventilation or ECMO, or death at 28 days, and the effect on overall survival were not statistically significant. Expand
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
TLDR
In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes. Expand
Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease
TLDR
The study showed that CP therapy appears to be safe and it is feasible to perform a definitive phase 3 clinical trial using this study protocol. Expand
Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial
TLDR
CP-SOC did not result in a higher proportion of clinical improvement on at day 28 in hospitalised patients with COVID-19 compared to SOC alone, and there was no significant difference between CP+SOC and SOC groups in prespecified secondary outcomes. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 30 REFERENCES
Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial.
TLDR
Among patients with severe or life-threatening COVID-19, convalescent plasma therapy added to standard treatment, compared with standard treatment alone, did not result in a statistically significant improvement in time to clinical improvement within 28 days. Expand
Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience
TLDR
The relationships between reduced mortality and both earlier time to transfusion and higher antibody levels provide signatures of efficacy for convalescent plasma in the treatment of hospitalized COVID-19 patients. Expand
Efficacy and safety of convalescent plasma for severe COVID-19 based on evidence in other severe respiratory viral infections: a systematic review and meta-analysis
TLDR
Studies of non-COVID-19 severe respiratory viral infections provide indirect, very low-quality evidence that raises the possibility that convalescent plasma has minimal or no benefit in the treatment of CO VID-19 and low- quality evidence that it does not cause serious adverse events. Expand
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.
TLDR
In this preliminary uncontrolled case series of 5 critically ill patients with COVID-19 and ARDS, administration of convalescent plasma containing neutralizing antibody was followed by improvement in their clinical status, and these observations require evaluation in clinical trials. Expand
Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study
TLDR
This clinical study provides strong evidence to support the efficacy of convalescent plasma therapy in COVID-19 patients and recommends this treatment for management of these patients. Expand
Convalescent Plasma for COVID-19. A randomized clinical trial
TLDR
The Convalescent-plasma-for-COVID study was a randomized trial comparing convalescent plasma with standard of care therapy in patients hospitalized for COVID-19 in the Netherlands and found no difference in mortality, hospital stay, or day-15 disease severity was observed between plasma treated patients and patients on standard of Care. Expand
Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
TLDR
To continually assess, as more evidence becomes available, whether convalescent plasma or hyperimmune immunoglobulin transfusion is effective and safe in treatment of people with COVID-19, a first living update of this review is published. Expand
Safety Update
TLDR
New data provide robust evidence that transfusion of convalescent plasma is safe in hospitalized patients with COVID-19, and support the notion that earlier administration of plasma within the clinical course of CO VID-19 is more likely to reduce mortality. Expand
Convalescent plasma in Covid-19: Possible mechanisms of action
TLDR
Convalescent plasma constitutes the first option in the current situation, since it has been successfully used in other coronaviruses outbreaks, and the benefits of PC are expected to be better achieved if used in non-critically hospitalized patients, in the hope of reducing morbidity and mortality. Expand
Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea.
TLDR
The transfusion of up to 500 ml of convalescent plasma with unknown levels of neutralizing antibodies in 84 patients with confirmed EVD was not associated with a significant improvement in survival, and no serious adverse reactions associated with the use of convalscent plasma were observed. Expand
...
1
2
3
...